Thierry Hercend

Directeur Général chez GamaMabs Pharma SA

Profil

Thierry Hercend is currently an Independent Non-Executive Director at Inotrem SA, Director at Grey Wolf Therapeutics Ltd., Director at U3 Pharma AG, Venture Partner at Andera Partners SCA since 2006, and General Manager at GamaMabs Pharma SA since 2021.
Former roles include Chairman at Poxel SA, Chairman-Supervisory Board at Cytomics Pharmaceuticals SA and Genticel SA, Scientific Director-Healthcare Division at Roussel Uclaf SA, Director at Oncoethix GmbH and Complix NV, Vice President-Research at Vertex Pharmaceuticals, Inc. from 1998 to 2002, Vice President at Aventis SA from 2002 to 2005, Professor-Immunology at Université de Paris XI Paris Sud, Principal at Laboratoire Français du Fractionnement et des Biotechnologies, Head-Hemato-Immunology Unit at Institut de Formation Supérieure BioMédicale, and Head-Hemato Immunology Unit at Institut Gustave Roussy EURL.
Education includes a doctorate from Université Paris 1 Panthéon-Sorbonne.

Postes actifs de Thierry Hercend

Sociétés	Poste	Début
Andera Partners SCA	Private Equity Investor	01/01/2006
GamaMabs Pharma SA	Directeur Général	25/09/2021
Inotrem SA	Directeur/Membre du Conseil	-
U3 Pharma AG	Directeur/Membre du Conseil	-
Grey Wolf Therapeutics Ltd.	Directeur/Membre du Conseil	-

Anciens postes connus de Thierry Hercend

Sociétés	Poste	Fin
Aventis SA	Corporate Officer/Principal	-
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	01/01/2002
Institut Gustave Roussy EURL	Corporate Officer/Principal	-
Université de Paris XI Paris Sud	Corporate Officer/Principal	-
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░	░░░░░░░░░░	-